Design and evaluation of a novel evodiamine-phospholipid complex for improved oral bioavailability. - Wikidata - awgldk - TriplyDB

Design and evaluation of a novel evodiamine-phospholipid complex for improved oral bioavailability.

Design and evaluation of a novel evodiamine-phospholipid complex for improved oral bioavailability.

http://www.wikidata.org/entity/Q34210271

about

Evodiamine induces G2/M arrest and apoptosis via mitochondrial and endoplasmic reticulum pathways in H446 and H1688 human small-cell lung cancer cells 20(S)-Protopanaxadiol Phospholipid Complex: Process Optimization, Characterization, In Vitro Dissolution and Molecular Docking Studies.Improvement of oral availability of ginseng fruit saponins by a proliposome delivery system containing sodium deoxycholate A promising antitumor activity of evodiamine incorporated in hydroxypropyl-β-cyclodextrin: pro-apoptotic activity in human hepatoma HepG2 cells.An optimized molecular inclusion complex of diferuloylmethane: enhanced physical properties and biological activity.Characterization, activity, and computer modeling of a molecular inclusion complex containing rifaldazine Preparation and characterization of tetrandrine-phospholipid complex loaded lipid nanocapsules as potential oral carriers.Evodiamine and Its Role in Chronic Diseases.Preparation, characterization, and anticancer efficacy of evodiamine-loaded PLGA nanoparticles.Luteolin-phospholipid complex: preparation, characterization and biological evaluation.Phospholipid Complex Technique for Superior Bioavailability of Phytoconstituents.Catan-ionic hybrid lipidic nano-carriers for enhanced bioavailability and anti-tumor efficacy of chemodrugs.Alkaloids isolated from natural herbs as the anticancer agents.Efficient intracellular delivery makes cancer cells sensitive to nanoemulsive chemodrugs Improved absorption and in vivo kinetic characteristics of nanoemulsions containing evodiamine-phospholipid nanocomplex.Long-circulating nanoliposomes (LCNs) sustained delivery of baicalein (BAI) with desired oral bioavailability in vivo.Phytochylomicron as a dual nanocarrier for liver cancer targeting of luteolin: in vitro appraisal and pharmacodynamics.Encapsulation of low lipophilic and slightly water-soluble dihydroartemisinin in PLGA nanoparticles with phospholipid to enhance encapsulation efficiency and in vitro bioactivity.Preparation and evaluation of luteolin-phospholipid complex as an effective drug delivery tool against GalN/LPS induced liver damage.A phospholipid complex to improve the oral bioavailability of flavonoids.

P2860

Q28542722-07EBDA6E-1574-4D9C-AEB1-1319214A6492 Q31138691-21519DAD-6ED5-4A1F-B422-5DF3B8890387 Q35917912-7FC2DF70-9032-4255-B936-9A386CCD5760 Q36085681-44D72CC4-4CCA-4087-92B6-17C847A6F0F9 Q36318232-C0031DAB-23C1-4EB6-B80F-79D36A976D57 Q36587699-B7D9E380-E995-46B2-BE08-179023F876E4 Q37278642-31757FA0-A43E-463E-BDA6-4C228D0BA5C6 Q38807050-3264BC38-1B85-4824-B34F-5ED3B281D541 Q38987697-1DC4CF74-C935-4868-8CBB-919D931D6A63 Q39175058-003DE4F0-6310-4693-8419-995106F61E00 Q39308835-E89C03E7-F7FA-4218-897E-926E70FF924C Q42223300-0A203BB1-A43E-483B-81C6-990BD496198E Q42324855-EFFF832F-7CCF-4456-AFEB-E52379F57546 Q42371499-D90207B7-15E6-41D5-A518-C4E7F7BE3248 Q42859890-51B0838E-2E03-4F5D-887E-6293A7FC1B33 Q45692707-1057BF9A-037C-4A11-B9A6-CFD61885880A Q49330500-D260DB08-DA9B-4818-AAB7-A53164148C4B Q53397034-20041886-3B2B-4EE9-8FE0-DE56AF816DFE Q53561486-E58FD3CC-EEDE-47AE-981F-FF835850CE3F Q53664881-1F8087E1-F204-4EF0-99BC-6B533CC1A2A7

P2860

Design and evaluation of a novel evodiamine-phospholipid complex for improved oral bioavailability.

http://www.wikidata.org/entity/Q34210271

description

2012 nî lūn-bûn

@nan

2012 թուականի Մարտին հրատարակուած գիտական յօդուած

@hyw

2012 թվականի մարտին հրատարակված գիտական հոդված

@hy

2012年の論文

@ja

2012年論文

@yue

2012年論文

@zh-hant

2012年論文

@zh-hk

2012年論文

@zh-mo

2012年論文

@zh-tw

2012年论文

@wuu

name

Design and evaluation of a nov ...... improved oral bioavailability.

@ast

Design and evaluation of a nov ...... improved oral bioavailability.

@en

Design and evaluation of a nov ...... improved oral bioavailability.

@nl

type

label

Design and evaluation of a nov ...... improved oral bioavailability.

@ast

Design and evaluation of a nov ...... improved oral bioavailability.

@en

Design and evaluation of a nov ...... improved oral bioavailability.

@nl

prefLabel

Design and evaluation of a nov ...... improved oral bioavailability.

@ast

Design and evaluation of a nov ...... improved oral bioavailability.

@en

Design and evaluation of a nov ...... improved oral bioavailability.

@nl

P1433

Q34210271-F48EE789-E436-4EC5-B177-89EA9132CE53

P1476

Q34210271-6A438F2B-A31C-4BEB-B8A9-407C1FCDBBB2

P2093

Q34210271-025DE4C9-7CD6-4C1B-B044-862B1CC6A069

Q34210271-03B06F6E-F02E-43E2-A9E1-003AE9D80C7C

Q34210271-28A07399-1B8C-4F57-BCA7-DBF853A5FC8D

Q34210271-88F044D6-D30E-4A93-99A6-31C5B59200D3

Q34210271-974522FF-A1F1-4BA2-8474-6198A0CCA301

Q34210271-BF04ED72-5D36-4AE7-8C7B-8A7750C9691D

Q34210271-E3AB6524-9926-4AE5-A3C7-979150363997

Q34210271-EED31CE0-F4DA-404E-B3F0-0010B48AA45C

Q34210271-F1D62FD7-99FF-4DBF-9BA9-12C940138028

P2860

Q34210271-1BC4A1DE-4007-4A6A-A7D7-1D3326F3BFC1

Q34210271-2254E628-05F2-47B8-8061-A5D19E803B0E

Q34210271-23CADF7C-AA52-4CE1-835B-20EBC4D26754

Q34210271-57204EF0-6C24-4A56-BE1D-32423FDF2758

Q34210271-5982EC5B-B58F-4709-B88F-EB6E4B8416C3

Q34210271-5DD22F76-3D00-48DA-9BEA-170726C75017

Q34210271-6C083AAA-1B25-40DA-A53A-878706DCB9B4

Q34210271-6C91A8D6-7D8A-4EFC-AF98-81EADA01FC99

Q34210271-8E35DCA3-E401-4072-B815-61E64F322AC3

Q34210271-BDB59F5F-7879-4144-A170-D877C781F726

P2888

Q34210271-C88CCA3C-6366-4617-9BA2-6B1CBA415D62

P304

Q34210271-B0E01717-9804-43E2-AB98-F258E5F66142

P31

Q34210271-067E01D3-C02A-4928-8EEA-E2222A9AE5C7

P356

Q34210271-FCAB7596-AAD4-4549-B63A-96ED2B23259C

P407

Q34210271-DDDCA1E4-3046-466F-A8C0-3945DFF7A53D

P433

Q34210271-4D3099BE-D462-411A-A9CF-07C7B06D395E

P478

Q34210271-125D3022-1542-45B4-9E21-D53DFE1738D8

P577

Q34210271-8BA43F1B-BC7D-4881-A6FB-184FECC61BDD

P5875

Q34210271-1F2CCEBD-6D42-4103-96B9-99BD43B24F96

P6179

Q34210271-F1EBE811-3CD1-4F0A-BB91-96DF93CD3AA2

P698

Q34210271-B9438826-5214-49CC-AD60-5369F809FF37

P932

Q34210271-7B4DB4D1-7131-48F2-9F7B-C10FA34C2045

P356

S12249-012-9772-9

P1433

AAPS PharmSciTech

P1476

Design and evaluation of a nov ...... improved oral bioavailability.

@en

P2093

Dan He

http://www.w3.org/2001/XMLSchema#string

Hong Wang

http://www.w3.org/2001/XMLSchema#string

Huafeng Yin

http://www.w3.org/2001/XMLSchema#string

Huarong Xiong

http://www.w3.org/2001/XMLSchema#string

Jingqing Zhang

http://www.w3.org/2001/XMLSchema#string

Mingjun Wu

http://www.w3.org/2001/XMLSchema#string

Qunyou Tan

http://www.w3.org/2001/XMLSchema#string

Shan Liu

http://www.w3.org/2001/XMLSchema#string

Xueliang Chen

http://www.w3.org/2001/XMLSchema#string

P2860

Preparation and properties of a silybin-phospholipid complex.

Mechanisms of phospholipid complex loaded nanoparticles enhancing the oral bioavailability.

Process optimization, characterization and pharmacokinetic evaluation in rats of ursodeoxycholic acid-phospholipid complex.

Evodiamine: a novel anti-cancer alkaloid from Evodia rutaecarpa.

Bioavailability and activity of phytosome complexes from botanical polyphenols: the silymarin, curcumin, green tea, and grape seed extracts.

Preparation, characterization and in vivo evaluation of bergenin-phospholipid complex.

Lyophilized paclitaxel magnetoliposomes as a potential drug delivery system for breast carcinoma via parenteral administration: in vitro and in vivo studies.

Preparation, characterization and evaluation of Marsupsin-phospholipid complex.

Determining the effects of lipophilic drugs on membrane structure by solid-state NMR spectroscopy: the case of the antioxidant curcumin.

The preparation of silybin-phospholipid complex and the study on its pharmacokinetics in rats.

P2888

s12249-012-9772-9

P304

534-547

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1208/S12249-012-9772-9

http://www.w3.org/2001/XMLSchema#string

P407

P433

2

http://www.w3.org/2001/XMLSchema#string

P478

13

http://www.w3.org/2001/XMLSchema#string

P577

2012-03-28T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

221979091

http://www.w3.org/2001/XMLSchema#string

P6179

1003818941

http://www.w3.org/2001/XMLSchema#string

P698

22454136

http://www.w3.org/2001/XMLSchema#string

P932

3364372

http://www.w3.org/2001/XMLSchema#string